{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:38:56Z","timestamp":1783381136440,"version":"3.54.6"},"reference-count":42,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"7","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2021,6,29]]},"DOI":"10.1167\/tvst.10.7.30","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T15:40:02Z","timestamp":1624981202000},"page":"30","source":"Crossref","is-referenced-by-count":33,"title":["Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration"],"prefix":"10.1167","volume":"10","author":[{"given":"Maximilian","family":"Pfau","sequence":"first","affiliation":[{"name":"Department of Biomedical Data Science, Stanford University, Palo Alto, CA, USA"},{"name":"Department of Ophthalmology, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Sahu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA"},{"name":"Department of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan Allozi","family":"Rupnow","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA"},{"name":"Department of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Romond","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Millet","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Schmitz-Valckenberg","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Bonn, Bonn, Germany"},{"name":"John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Fleckenstein","sequence":"additional","affiliation":[{"name":"John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer I.","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"de Sisternes","sequence":"additional","affiliation":[{"name":"Carl Zeiss Meditec AG, Dublin, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Leng","sequence":"additional","affiliation":[{"name":"Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Rubin","sequence":"additional","affiliation":[{"name":"Department of Biomedical Data Science, Stanford University, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle A.","family":"Hallak","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/phar.1264","article-title":"Age-related macular degeneration","volume":"33","author":"Cheung","year":"2013","journal-title":"Pharmacotherapy"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1172\/JCI71029","article-title":"Recent developments in the treatment of age-related macular degeneration","volume":"124","author":"Holz","year":"2014","journal-title":"J Clin Invest"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/j.ophtha.2013.05.018","article-title":"A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration","volume":"120","author":"Rasmussen","year":"2013","journal-title":"Ophthalmology"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology","volume":"126","author":"Bakri","year":"2019","journal-title":"Ophthalmology"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ajo.2013.05.037","article-title":"One year follow-up of functional recovery in neovascular AMD during monthly anti-VEGF treatment","volume":"156","author":"Munk","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"key":"bib9","first-page":"1573","article-title":"ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD)","volume":"104","author":"Liakopoulos","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00347-017-0610-z","article-title":"Reasons for delayed and discontinued therapy in age-related macular degeneration","volume":"115","author":"Wintergerst","year":"2018","journal-title":"Ophthalmologe"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder Clinical Trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1016\/j.ajo.2020.05.012","article-title":"Is This a 737 Max Moment for Brolucizumab?","volume":"216","author":"Rosenfeld","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.cell.2018.02.010","article-title":"Identifying medical diagnoses and treatable diseases by image-based deep learning","volume":"172","author":"Kermany","year":"2018","journal-title":"Cell"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41591-018-0107-6","article-title":"Clinically applicable deep learning for diagnosis and referral in retinal disease","volume":"24","author":"De Fauw","year":"2018","journal-title":"Nat Med"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41591-020-0867-7","article-title":"Predicting conversion to wet age-related macular degeneration using deep learning","volume":"26","author":"Yim","year":"2020","journal-title":"Nat Med"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1001\/jamaophthalmol.2019.0868","article-title":"Imaging, genetic, and demographic factors associated with conversion to neovascular age-related macular degeneration: secondary analysis of a randomized clinical trial","volume":"137","author":"Hallak","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.ophtha.2017.12.034","article-title":"Predicting visual acuity by using machine learning in patients treated for neovascular age-related macular degeneration","volume":"125","author":"Rohm","year":"2018","journal-title":"Ophthalmology"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ajo.2020.04.003","article-title":"Determinants of cone- and rod-function in geographic atrophy: AI-based structure-function correlation","volume":"217","author":"Pfau","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"11132","DOI":"10.1038\/s41598-019-47565-y","article-title":"Artificial intelligence for morphology-based function prediction in neovascular age-related macular degeneration","volume":"9","author":"von der Emde","year":"2019","journal-title":"Sci Rep"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1167\/iovs.61.5.63","article-title":"Determinants of quality of life in geographic atrophy secondary to age-related macular degeneration","volume":"61","author":"K\u00fcnzel","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1167\/iovs.16-21053","article-title":"Prediction of anti-VEGF treatment requirements in neovascular AMD using a machine learning approach","volume":"58","author":"Bogunovic","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1167\/iovs.15-18593","article-title":"Distinct genetic risk profile of the rapidly progressing diffuse-trickling subtype of geographic atrophy in age-related macular degeneration (AMD)","volume":"57","author":"Fleckenstein","year":"2016","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"e0133968","DOI":"10.1371\/journal.pone.0133968","article-title":"Treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the USA","volume":"10","author":"Ferreira","year":"2015","journal-title":"PLoS One"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1136\/bjophthalmol-2016-309818","article-title":"UK AMD\/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice","volume":"101","author":"Lee","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1001\/jamaophthalmol.2020.2914","article-title":"Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration","volume":"138","author":"Pfau","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/tvst.4.5.2","article-title":"Restricted Summed-Area Projection for Geographic Atrophy Visualization in SD-OCT Images","volume":"4","author":"Chen","year":"2015","journal-title":"Transl Vis Sci Technol"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J Stat Softw"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach Learn"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial","volume":"138","author":"Khanani","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40942-020-00221-4","article-title":"New frontiers in retina: highlights of the 2020 angiogenesis, exudation and degeneration symposium","volume":"6","author":"Puliafito","year":"2020","journal-title":"Int J Retin Vitr"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ajo.2019.03.006","article-title":"Three-year follow-up of phase 1 and 2a rAAV.sFLT-1 Subretinal Gene Therapy Trials for Exudative Age-Related Macular Degeneration","volume":"204","author":"Rakoczy","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","article-title":"Association of baseline characteristics and early vision response with 2-year vision outcomes in the Comparison of AMD Treatments Trials (CATT)","volume":"122","author":"Ying","year":"2015","journal-title":"Ophthalmology"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19780","article-title":"A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)","volume":"19","author":"Chakravarthy","year":"2015","journal-title":"Health Technol Assess"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","article-title":"Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study","volume":"33","author":"Cohen","year":"2013","journal-title":"Retina"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/ceo.2018.46.issue-2","article-title":"Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of \u2018expanded spectra\u2019\u2014a review","volume":"46","author":"Dansingani","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"bib41","first-page":"178","article-title":"Clinical characteristics of polypoidal choroidal vasculopathy and anti-vascular endothelial growth factor treatment response in Caucasians.","volume":"243","author":"Kokame","year":"2020","journal-title":"Int J Ophthalmol Zeitschrift fur Augenheilkd"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajo.2020.12.012","article-title":"Automated quantitative assessment of retinal fluid volumes as important biomarkers in neovascular age-related macular degeneration","volume":"224","author":"Keenan","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"bib23","article-title":"NGBoost: natural gradient boosting for probabilistic prediction","author":"Duan","year":"2019"},{"key":"bib24","article-title":"XGBoostLSS \u2013 An extension of XGBoost to probabilistic forecasting","author":"Marz","year":"2019"},{"key":"bib33","article-title":"{pls}: Partial Least Squares and Principal Component regression","author":"Mevik","year":"2011"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2776413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T15:40:05Z","timestamp":1624981205000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2776413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.10.7.30","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,29]]}}}